Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study-Reference-Cited by-同舟云学术

Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

Published:2024-04 Issue:4 Volume:11 Page:e276-e286
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Bazinet Alexandre,Garcia-Manero Guillermo,Short Nicholas,Alvarado Yesid,Bataller Alex,Abuasab Tareq,Islam Rabiul,Montalbano Kathryn,Issa Ghayas,Maiti Abhishek,Yilmaz Musa,Jain Nitin,Masarova Lucia,Kornblau Steven,Jabbour Elias,Montalban-Bravo Guillermo,Rausch Caitlin R,Pierce Sherry,DiNardo Courtney D,Kadia Tapan,Daver Naval,Konopleva Marina,Huang Xuelin,Kantarjian Hagop,Ravandi Farhad

Funder

University of Texas MD Anderson Cancer Center

Publisher

Elsevier BV

Reference36 articles.

1. Acute Myeloid Leukemia;Döhner;N Engl J Med,2015

2. Age and acute myeloid leukemia;Appelbaum;Blood,2006

3. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry;Hulegårdh;Am J Hematol,2015

4. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia;Tsai;Leukemia,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

2. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17

3. Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia;The Lancet Haematology;2024-04